ClinicalTrials.gg
WithdrawnNCT02095574Updated Aug 13, 2014

A Pharmacokinetic Study to Access How the Body Absorbs and Removes ABT-199 in Adults With Non-Hodgkin's Lymphoma

A Phase 1 interventional study of [14C]ABT-199 (GDC-0199) in Relapsed/Refractory Non-Hodgkin's Lymphoma, sponsored by AbbVie. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-08-13.

Sponsored by AbbVie · Phase 1, Interventional, and Basic science

Why this study was withdrawn
This study will now be conducted in healthy volunteers.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing venetoclax in Lymphoma, Non-Hodgkin — 3 open to participants now, 5 under way, 1 of them phase 3. venetoclax · Lymphoma, Non-Hodgkin.

Enrollment
22nd of 23
0 · median 25
Started
2014
with 2 others
Phase 1
15 of 23
2 open now
Registered
6th of 23
by date
Lead sponsor
10 of 23
AbbVie

Among the 23 studies testing venetoclax in Lymphoma, Non-Hodgkin, this one is the 22nd largest by enrollment, is one of 3 that started in 2014, is one of 15 in phase 1, and was the 6th registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

3 of the 23 studies testing venetoclax in Lymphoma, Non-Hodgkin are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About venetoclax

venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing venetoclax in Lymphoma, Non-Hodgkin, or all of them as a file.
02

Study summary

A pharmacokinetic study to access how the body absorbs and removes ABT-199 in adults with Non-Hodgkin's Lymphoma.

03

Conditions studied

  • Relapsed/Refractory Non-Hodgkin's Lymphoma

Keywords

  • GDC-0199
  • ADME
  • Relapsed
  • Refractory
  • ABT-199
  • Non-Hodgkin's Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject must have disease.
  2. Subject must have documented diagnosis of non-hodgkin's lymphoma as defined by a B-cell neo-plasm in the World Health Organization (WHO) classification scheme except as noted in exclusion criteria.
  3. Subject has an (ECOG) performance score of 0-2.
  4. Subject has adequate bone marrow (independent of growth factor support per local laboratory reference range).
  5. Subject has adequate coagulation, renal and hepatic function.

Exclusion criteria

Exclusion Criteria:

  1. Subject has been diagnosed with Post-Transplant Lymphoproliferative Disease (PTLD), Burkitt's lymphoma, Burkitt-like lymphoma, lymphoblastic lymphoma/leukemia, chronic lymphocytic leukemia (CLL), mantle cell leukemia (MCL), or small lymphocytic lymphoma (SLL).
  2. Subject has undergone an stem cell transplant.
  3. Subject is receiving combination anti-retroviral therapy for (HIV) (due to potential drug-drug interactions, as well as the potential for increased risk of opportunistic infections).
  4. Subject has a significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, cardiovascular, or hepatic disease within 6 months that in the opinion of the Investigator would adversely affect his/her participation in this study.
  5. Subject has active peptic ulcer disease or other hemorrhagic esophagitis/gastritis.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    [14C]ABT-199

    Subjects with relapsed or refractory Non-Hodgkin's Lymphoma

    Drug: [14C]ABT-199 (GDC-0199)

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax) of ABT-199 and [14C]ABT-199

    Time frame: For approximately 9 days following a single oral dose of [14C]ABT-199

  2. Time to Cmax (Tmax) for ABT-199 and [14C]ABT-199

    Time frame: For approximately 9 days following a single oral dose of [14C]ABT-199

  3. Area Under the Time curve (AUC) for ABT-199 and [14C]ABT-199

    The area under the exposure-time curve from time zero to Day 9 and time zero extrapolated to infinite time for single dose of \[14C\]ABT-199

    Time frame: For approximately 9 days following a single oral dose of [14C]ABT-199

Secondary outcomes

  1. Number of subjects with adverse events

    Adverse event monitoring, lab test assessment, physical exam and vital signs will be evaluated throughout the study.

    Time frame: At each visit (daily for approximately the first 9 days)

  2. Percentage of subjects with adverse events

    Adverse event monitoring, lab test assessment, physical exam and vital signs will be evaluated throughout the study.

    Time frame: At each visit (daily for approximately the first 9 days)

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2014, a primary completion of Sep 2014 and a completion of Jan 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2014
First posted
Mar 26, 2014
Start
Sep 2014
Primary completionEst.
Sep 2014
CompletionEst.
Jan 2015
Last update
Aug 13, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02095574
Lead sponsor
AbbVie
Collaborators
Genentech, Inc.
Responsible party
Sponsor
First posted
Mar 26, 2014
Start date
Sep 2014
Primary completion
Sep 2014 (estimated)
Completion
Jan 2015 (estimated)
Last update
Aug 13, 2014

Study contacts

Justin L Ricker, MD
study director · AbbVie

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Venetoclax

Start the discussion